Areas of Expertise
  • Personalized targeted therapies and smart drugs
  • Immunotherapies
  • Breast cancer
  • Lung cancer
  • Colorectal cancer
  • Stomach cancers
  • Gynecological cancers
  • Genitourinary cancers

Education and Specialization

  • 2005–2011: Istanbul University, Cerrahpaşa Faculty of Medicine – Medical Education

  • 2012–2013: 19 Mayıs University – Orthopedics and Traumatology

  • 2014–2018: University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital – Residency / Specialization

  • 2020–2023: University of Health Sciences, Antalya Training and Research Hospital

Experience

  • 2011–2012: Fatsa State Hospital

  • 2013–2014: Fatsa State Hospital

  • 2018–2020: Şırnak State Hospital

  • 2020–2020: Fatsa State Hospital

  • 2023–2025: Ordu State Hospital

Professional Memberships

  • Ordu Medical Chamber

Clinical Trials and Research Projects

  • Phase III Clinical Trial (2025–Present): A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both in Combination with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy.

    • Role: Sub-Investigator

  • TRIMPACT Study (2025–Present): A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line Treatment (Stage 4) in Non-Small Cell Lung Cancer (NSCLC) Patients with PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations.

    • Role: Sub-Investigator

Resume

Education and Specialization

  • 2005–2011: Istanbul University, Cerrahpaşa Faculty of Medicine – Medical Education

  • 2012–2013: 19 Mayıs University – Orthopedics and Traumatology

  • 2014–2018: University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital – Residency / Specialization

  • 2020–2023: University of Health Sciences, Antalya Training and Research Hospital

Experience

  • 2011–2012: Fatsa State Hospital

  • 2013–2014: Fatsa State Hospital

  • 2018–2020: Şırnak State Hospital

  • 2020–2020: Fatsa State Hospital

  • 2023–2025: Ordu State Hospital

Professional Memberships

  • Ordu Medical Chamber

Publications

Clinical Trials and Research Projects

  • Phase III Clinical Trial (2025–Present): A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Giredestrant Compared with Fulvestrant, Both in Combination with a CDK4/6 Inhibitor, in Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy.

    • Role: Sub-Investigator

  • TRIMPACT Study (2025–Present): A Prospective Real-World Study of Atezolizumab Monotherapy as First-Line Treatment (Stage 4) in Non-Small Cell Lung Cancer (NSCLC) Patients with PD-L1 Tumor Cell Expression ≥50% and No Targetable Mutations.

    • Role: Sub-Investigator

Quick Appointment
Randevu alabilmek için hastane ve branş seçmeniz gerekmektedir.
Create an Appointment
Calendar

Thank You

We will contact you as soon as possible. We wish you healthy days!